ALAMEDA, Calif., April 19 /PRNewswire-FirstCall/ -- Avigen, Inc. , a biopharmaceutical company developing innovative therapies for the treatment of neurological conditions, will hold its quarterly conference call to discuss first quarter results on Tuesday, April 24, 2007, at 11:30 a.m. EDT (8:30 a.m. PDT). Kenneth Chahine, Chief Executive Officer, and Michael Coffee, Chief Business Officer, can be heard by calling 800-706- 7745 (U.S.) or 617-614-3472 (non-U.S. locations) using passcode 12207133.
This call is being webcast by Thomson/CCBN and can be accessed at Avigen’s website at www.avigen.com. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.
A rebroadcast of the call will be available shortly after the conclusion of the session. The replay may be accessed over the Internet at www.avigen.com or by calling 888-286-8010 (U.S.) or 617-801-6888 (non-U.S. locations) using passcode 60387595.
About Avigen
Avigen, Inc. is a biopharmaceutical company focused on unique small molecule therapeutics and biologics to treat serious, chronic neurological disorders, including neuropathic pain and neuromuscular spasm and spasticity. For press releases and other corporate information, visit our website at http://www.avigen.com.
Avigen, Inc.
CONTACT: Michael Coffee, Chief Business Officer of Avigen, Inc.,+1-510-748-7372 or ir@avigen.com
Web site: http://www.avigen.com/
